Contact

Used Services and Cookies

Our website uses cookies to enhance your user experience. Some cookies are essential for the operation and management of the site, while others are used for anonymous statistics or personalized content. You can choose which types of cookies you wish to accept. Please note that limiting cookie use may impair certain functions of the website.

More information:

Essential cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website or, for example, saving your cookie settings. The website cannot function properly without these cookies. This category cannot be deactivated.
  • Name:
    ukie_a_cookie_consent_manager
  • Duration:
    30 days
  • Domain:
    [Your Domain]
  • Provider:
    [Your Organization]
  • Purpose:
    Stores the cookie preferences of website visitors.
  • Name:
    ukie_category_consent_*
  • Duration:
    30 days
  • Domain:
    [Your Domain]
  • Provider:
    [Your Organization]
  • Purpose:
    Stores more cookie settings of website visitors, when removing content blockers.
  • Name:
    *_session
  • Duration:
    2 hours
  • Domain:
    [Your Domain]
  • Provider:
    [Your Organization]
  • Purpose:
    The session cookie is essential for the basic functioning of the website. It allows users to navigate through the site and use its basic features.
  • Name:
    XSRF-TOKEN
  • Duration:
    2 hours
  • Domain:
    [Your Domain]
  • Provider:
    [Your Organization]
  • Purpose:
    This cookie serves security purposes and aids in preventing Cross-Site Request Forgery (CSRF) attacks. It is a technical necessity.
Studies & Guidelines
Studies & Guidelines

Evidence-based. Guideline-compliant.

Stronger together in telemedicine

Our telemonitoring solutions significantly improve the quality of care for patients with heart disease. The benefits of telemonitoring have been examined and confirmed in numerous studies. As a result, both the European and German cardiology societies have incorporated corresponding recommendations into their clinical guidelines.

Patient with heart failure uses a tablet to assess her health status.

IN-TIME study – Reduction of mortality by 60%

The IN-TIME study, conducted using BIOTRONIK Home Monitoring®, was the first randomized controlled trial to demonstrate a mortality benefit for heart failure patients through automatic, daily, implant-based, multiparametric telemonitoring. Thanks to Home Monitoring, arrhythmias and suboptimal therapies could be detected at an early stage, leading to a significant reduction in all-cause mortality.¹

Key findings of the IN-TIME study:

A significant reduction in all-cause mortality by more than 60% in patients with heart failure, as well as a positive effect on the composite clinical score, achieved through implant-based (ICD or CRT-D) BIOTRONIK Home Monitoring® compared with standard care.

Studies & Guidelines

TIM-HF2 – Successful use with external measuring devices

For patients who do not have implants, the TIM-HF2 study demonstrated the benefits of telemonitoring (TM) using external devices such as ECG recorders, scales, and blood pressure monitors. TIM-HF2 showed that telemonitoring can significantly reduce mortality and also lead to fewer lost days due to cardiovascular events or death (17.8 vs. 24.2 days; p = 0.046). Patients receiving telemedical care lost only 3.8 days per year due to heart-failure–related hospitalizations, compared with 5.6 days in the control group.²

The external sensors from GETEMED, which are used for telemonitoring within inCareNet HF, proved highly effective in the TIM-HF2 study.

Studies & Guidelines
Contact

Do you want to learn more?

If you like to learn more about inCareNet HF, feel free to contact us via our contact form.

Contact us

ESC Guidelines 2021 & EHRA Recommendations 2023

Based on the numerous positive study results, the European Society of Cardiology (ESC) recommends in its 2021 guidelines that patients with heart failure should be integrated into a structured care program.³ This includes telemonitoring, as it reduces the risks of hospitalizations and premature death. The ESC assigns this recommendation the highest level of evidence (Class I, Level A).

Building on the ESC guidelines, the European Heart Rhythm Association (EHRA) also recommends telemonitoring for patients with active implants (ICD, pacemakers, ILRs, CRT devices) — likewise with a Class I, Level A recommendation. The EHRA even refers to telemonitoring for implant patients as the “standard of care.”

Recommended multidisciplinary measures for the management of chronic heart failure (HF), as well as for exercise-based rehabilitation in patients with chronic heart failure (ESC Guidelines 2021).

Reccomendations
Class
Level
It is recommended that patients with heart failure be enrolled in a multidisciplinary heart-failure management program to reduce the risk of heart-failure hospitalization and death.
I
A
It is recommended that patients with heart failure be enrolled in a multidisciplinary HF management program to reduce the risk of HF-related hospitalization and death.
I
A
Programs that can be carried out either at home and/or in the clinic provide a benefit and are recommended to reduce the risk of heart-failure–related hospitalizations and death.
I
A

HF= Heart Failure